Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.84 -0.15 (-3.01%)
As of: Sep 30, 2026 · 1:35 PM EDT

Taysha Gene Therapies, Inc. (TSHA) EBIT Margin (2023 - 2025)

Updated

Taysha Gene Therapies (TSHA) reported EBIT Margin of -515.95% for Q4 2025, up 469.80 percentage points from -985.76% a year earlier.

Analysis

Taysha Gene Therapies, Inc. (TSHA) EBIT Margin (2023 - 2025) Analysis & Trends

For FY2025, Taysha Gene Therapies posted EBIT Margin of -1130.65%, down 33.09 percentage points from FY2024.

  • EBIT Margin has a three-year change of +5362.04 percentage points (FY2022 to FY2025).
  • By year, EBIT Margin came in at -1097.55% in FY2024 (-628.72 pp), -468.83% in FY2023 (+6023.86 pp) and -6492.69% in FY2022.
  • The Q4 2025 figure ranks as the highest quarterly EBIT Margin since Q4 2023.
  • Year over year, EBIT Margin gained in two of the last seven quarters, with an average year-over-year change of -302.94 percentage points.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -515.95%
Jun 30, 2025 -1,347.08%
Mar 31, 2025 -930.54%
Dec 31, 2024 -985.76%
Sep 30, 2024 -1,448.43%
Jun 30, 2024 -1,915.38%
Mar 31, 2024 -713.28%
Dec 31, 2023 -450.78%
Sep 30, 2023 -342.39%
Jun 30, 2023 -976.37%
Mar 31, 2023 -351.87%
API Access

Taysha Gene Therapies, Inc. EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=TSHA&period=max&api_key=YOUR_API_KEY